AbbeyMoor receives approval for design improvements to ‘The Spanner’ prostatic stent

NewsGuard 100/100 Score

AbbeyMoor Medical Inc., a developer and manufacturer of medical devices for the management and treatment of prostatic obstruction, announced today that it has received PMA approval from the US Food and Drug Administration (FDA) for design changes to their flagship product, The Spanner Prostatic Stent.

"These changes are aimed at further improving patient comfort over the current highly accepted levels," said Darren Cook, director of marketing with the company. "Our goal is to hear an even greater percentage of our patient's state that they are not aware of the device's presence." According to Mark Whalen, VP of product development with the company, "The approved changes to the device result in a significant increase in flexibility over the current Spanner design with no impact to the ease of delivery and removal of the device." The Spanner™ temporary prostatic stent

The Spanner is a temporary prostatic stent designed to aid men who are experiencing difficulty in urination due to prostatic obstruction. Device placement can be performed in a physician office and does not require cystoscopy or anesthesia for placement. The Spanner is an alternative to indwelling catheterization, intermittent catheterization, or the use of a suprapubic tube in some patients.

The Spanner temporary prostatic stent has been designed to open the prostatic urethra and allow patients to maintain urine flow and allow volitional voiding by reducing urethral resistance within the prostate. As shown in the figure to the right the Spanner has a proximal balloon which is seated in the bladder neck to properly position the stent in the prostatic urethra. The stent extends from the bladder to just above the external sphincter. Device tethers (suture material) traverse the external sphincter to allow normal sphincter function, thus providing patients the ability to volitionally void. The distal anchor of the device is positioned in the bulbar urethra, just below the sphincter, to prevent device movement and migration into the bladder.

http://www.thespanner.com/ and http://www.abbeymoormedical.com/

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Intravascular imaging during PCI in heart disease patients improves survival, reduces adverse outcomes